BioAtla (NASDAQ:BCAB) Stock Price Down 1.3% – Time to Sell?

BioAtla, Inc. (NASDAQ:BCAB)’s share price was down 1.3% during mid-day trading on Monday . The stock traded as low as $1.31 and last traded at $1.48. Approximately 18,692 shares were traded during trading, a decline of 68% from the average session volume of 57,597 shares. The stock had previously closed at $1.50.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioAtla in a report on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $200.00.

BioAtla Trading Down 1.3%

The business has a 50 day simple moving average of $2.97 and a two-hundred day simple moving average of $4.60. The company has a market cap of $2.47 million, a PE ratio of -0.06 and a beta of 0.71.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.64. The business had revenue of $6.50 million during the quarter, compared to analysts’ expectations of $6.50 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BioAtla stock. ADAR1 Capital Management LLC boosted its stake in BioAtla, Inc. (NASDAQ:BCAB) by 24.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 228,107 shares of the company’s stock after purchasing an additional 45,000 shares during the quarter. ADAR1 Capital Management LLC owned about 13.74% of BioAtla worth $37,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.